Health score, price, valuation, risk signals, and key metrics at a glance.
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. It has a collaboration with Creatv Bio. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Balance Sheet & Red Flags (8/25); weakest: Growth (4/25).
Today's multiple positioned against its own trailing range — a visual premium/discount check.
Currently near its 5-quarter median.
Data-driven signals worth keeping an eye on across the last 8 quarters
Operating margins dropped 499.3% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.
Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.
as of May 2026
Revenue, EBITDA, operating income, net income, EPS, and shares
Gross, EBITDA, operating, and net margin trends
P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield
Total assets, cash, debt, book value, and leverage
Operating cash flow, free cash flow, FCF margin, and earnings quality
The last 7 consecutive quarters had negative FCF — the company is burning cash and may need external funding.
Shares outstanding increased 20.6% — significant dilution, likely from stock compensation or capital raises.
